Degeneration theory

ORYZON to Present New Clinical Data and Corporate Updates at International Conferences in September and October

Retrieved on: 
Wednesday, September 22, 2021

Oryzon will present preliminary data from the ongoing collaboration with INGEMM in Phelan McDermid Syndrome (PMS) at the International Conference on Autism, ICA-2021, which will be held on September 23-24.

Key Points: 
  • Oryzon will present preliminary data from the ongoing collaboration with INGEMM in Phelan McDermid Syndrome (PMS) at the International Conference on Autism, ICA-2021, which will be held on September 23-24.
  • The communication entitled "Phenotype and Psychometric Characterization of Phelan McDermid Syndrome Patients" will be presented by Dr. Carlos Buesa, Oryzons CEO.
  • Executive directors of the company will attend the BIO Spain 2021 event, which will take place September 27-October 1.
  • The company will moderate a KOL panel discussion on precision medicine therapeutic approaches for CNS disorders and the potential of LSD1 inhibitors like vafidemstat.

Inspirational Guidebook Provides Helpful Tools on Living Life to the Fullest with Macular Degeneration

Retrieved on: 
Monday, January 11, 2021

In Doris Winn Polaks new book, Living Life Fully with Macular Degeneration, she offers a comprehensive guide to assist individuals who are diagnosed or know a loved one with this eye disease.

Key Points: 
  • In Doris Winn Polaks new book, Living Life Fully with Macular Degeneration, she offers a comprehensive guide to assist individuals who are diagnosed or know a loved one with this eye disease.
  • Polak provides coping mechanisms for individuals losing their vision by providing tools to understand and adjust to this new lifestyle.
  • Living Life Fully with Macular Degeneration will also help family members learn how important it is to be there for their loved ones while adjusting to this new way of living.
  • Ultimately, Living Life Fully with Macular Degeneration shares the truth behind Polaks diagnosis.

Global Cartilage Degeneration Therapy Industry

Retrieved on: 
Tuesday, December 1, 2020

Degeneration Therapy by Geographic Region - France, Germany,

Key Points: 
  • Degeneration Therapy by Geographic Region - France, Germany,
    Therapy by Geographic Region - France, Germany, Italy, UK and
    Degeneration Therapy by Type - Joint Replacements,
    Therapy by Type - Joint Replacements, Chondroplasty,
    Degeneration Therapy by Application - Knee, Hip and Other
    Therapy by Application - Knee, Hip and Other Applications
    for Knee, Hip and Other Applications for the Years 2012, 2020 &
    Degeneration Therapy by Type - Joint Replacements,
    Therapy by Type - Joint Replacements, Chondroplasty,
    Degeneration Therapy by Application - Knee, Hip and Other
    Therapy by Application - Knee, Hip and Other Applications
    for Knee, Hip and Other Applications for the Years 2012, 2020 &
    Degeneration Therapy by Type - Joint Replacements,
    Therapy by Type - Joint Replacements, Chondroplasty,
    Other Types for the Years 2012, 2020 & 2027
    Degeneration Therapy by Application - Knee, Hip and Other
    Therapy by Application - Knee, Hip and Other Applications
    Degeneration Therapy by Type - Joint Replacements,
    Therapy by Type - Joint Replacements, Chondroplasty,
    Degeneration Therapy by Application - Knee, Hip and Other
    Therapy by Application - Knee, Hip and Other Applications
    for Knee, Hip and Other Applications for the Years 2012, 2020 &
    Degeneration Therapy by Type - Joint Replacements,
    by Type - Joint Replacements, Chondroplasty, Osteochondral
    Degeneration Therapy by Application - Knee, Hip and Other
    for Knee, Hip and Other Applications for the Years 2012, 2020 &
    Cartilage Degeneration Therapy by Type - Joint Replacements,
    Degeneration Therapy by Type - Joint Replacements,
    Other Types for the Years 2012, 2020 & 2027
    Cartilage Degeneration Therapy by Application - Knee, Hip and
    Degeneration Therapy by Application - Knee, Hip and Other
    Degeneration Therapy by Type - Joint Replacements,
    Degeneration Therapy by Type - Joint Replacements,
    Other Types for the Years 2012, 2020 & 2027
    Degeneration Therapy by Application - Knee, Hip and Other
    Degeneration Therapy by Application - Knee, Hip and Other
    Cartilage Degeneration Therapy by Type - Joint Replacements,
    Degeneration Therapy by Type - Joint Replacements,
    Other Types for the Years 2012, 2020 & 2027
    Cartilage Degeneration Therapy by Application - Knee, Hip and
    Degeneration Therapy by Application - Knee, Hip and Other

The South & Central America cartilage degeneration market is expected to reach US$ 1,195.57 million by 2027 from US$ 959.32 million in 2019

Retrieved on: 
Tuesday, November 24, 2020

NEW YORK, Nov. 24, 2020 /PRNewswire/ -- The South & Central America cartilage degeneration market is expected to reach US$ 1,195.57 million by 2027 from US$ 959.32 million in 2019.

Key Points: 
  • NEW YORK, Nov. 24, 2020 /PRNewswire/ -- The South & Central America cartilage degeneration market is expected to reach US$ 1,195.57 million by 2027 from US$ 959.32 million in 2019.
  • The cartilage degeneration market is growing primarily due to the increasing prevalence of sports injuries and obesity in South & Central America.
  • The growing prevalence of obesity is likely to accelerate the incidence of cartilage degeneration, which will drive the market growth.
  • A few of the major secondary sources associated with the South & Central America cartilage degeneration market report are the World Health Organization (WHO), and others.